Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Strategies for Treating Myc-Positive DLBCL

January 16th 2015

Utility of MRD in Mantle Cell Lymphoma

January 16th 2015

Improving Outcomes in Mantle Cell Lymphoma

January 16th 2015

Translating Novel CLL Therapies to Other Types of NHL

January 16th 2015

Indolent Non-Hodgkin's Lymphoma Treatment Selection

January 16th 2015

Assessing Response With Novel Agents in CLL

January 16th 2015

Role of NOTCH1 Mutations in CLL

January 16th 2015

Novel Treatment Approaches to Relapsed/Refractory CLL

January 16th 2015

Strategies for Managing Immune Thrombocytopenia in CLL

January 16th 2015

Maintenance Therapy in Chronic Lymphocytic Leukemia

January 16th 2015

Role of Transplantation in High-Risk CLL

January 16th 2015

Optimizing Treatment With Ibrutinib in High-Risk CLL

January 16th 2015

Safety and Efficacy of Obinutuzumab in CLL

January 16th 2015

First-Line Treatment Selection in CLL

January 16th 2015

Introduction: Upfront Treatment in Patients With CLL

January 16th 2015

Optimal Rituximab Dose in Lymphoma

December 24th 2014

Rituximab dose should be based on age and sex.

Dr. Ian Flinn Discusses Duvelisib Monotherapy in iNHL

December 9th 2014

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Frontline Idelalisib Monotherapy Yields High Response Rates in Older Patients With CLL, SLL

December 7th 2014

Idelalisib monotherapy shows activity in treatment-naÃ¯ve patients â‰¥65 years with CLL or SLL, with nearly 90% of patients enrolled in a phase II study demonstrating a partial response.

Dr. van den Brink Highlights Five Abstracts From ASH 2014

December 1st 2014

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, provides an overview of five notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

Treatments for Follicular Lymphoma Continue to Evolve

November 13th 2014

A growing understanding of follicular lymphoma pathogenesis is resulting in new drug candidates and approaches to clinical treatment.